Ex-vivo Effect of New Oral Anticoagulants on Point-of-care Devices
Ex-vivo Effect of New Oral Anticoagulants on Point-of-care Devices
Concentration determinations of anticoagulants require plasma instead of whole blood, and
 results are not immediately available to clinicians. Monitoring anticoagulants concentration
 along with bedside methods may provide an alternative guide for administration of the NOAC.

 The purpose of this investigation is to compare bedside coagulation assays in whole blood
 with plasma concentrations of the new oral anticoagulants (NOAC) in patients treated with
 therapeutic dosis of NOAC.
This open-label study will be performed by ex vivo investigations. Patients receiving the
 NOAC as dabigatran or rivaroxaban in therapeutic doses are recruited and informed consent of
 two blood sampling times will be obtained in correlation to the time of drug intake (two and
 24 hours after drug intake). The bedside measurements will be performed and compared directly
 with the concentrations determined by plasma concentration assays. These investigations will
 be performed at the department of Angiology at the university hospital Frankfurt.
The indication for the use of NOAC is provided by the attending physician. The criteria for
 inclusion and exclusion criteria for the use of the new oral anticoagulants must meet
 appropriate eligibility criteria and the clinical guidelines that are described in the
 SOPs.

 Patients treated with dabigatran 2x150mg / d for the prevention of stroke and systemic
 embolism in non-valvular atrial fibrillation are included.

 Moreover, patients treated with rivaroxaban 20 mg / d for DVT prophylaxis and treatment of
 recurrent DVT or PE are included.